NKGen Biotech, Inc.
NKGN
$0.1151
-$0.0146-11.26%
| Weiss Ratings | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.25 | |||
| Price History | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -30.62% | |||
| 30-Day Total Return | -78.43% | |||
| 60-Day Total Return | -77.34% | |||
| 90-Day Total Return | -71.23% | |||
| Year to Date Total Return | -83.34% | |||
| 1-Year Total Return | -91.01% | |||
| 2-Year Total Return | -98.87% | |||
| 3-Year Total Return | -98.82% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -94.08% | |||
| 52-Week Low % Change | 31.94% | |||
| Price | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.19 | |||
| 52-Week Low Price | $0.10 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | May 23, 2024 | |||
| Valuation | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.83M | |||
| Enterprise Value | 36.56M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.31 | |||
| Earnings Per Share Growth | -49.95% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.10 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.12 | |||
| Enterprise Value/EBITDA (TTM) | -1.21 | |||
| Enterprise Value/EBIT | -1.17 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 41.33M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 949-396-6830 | |||
| Address | 3001 Daimler Street Santa Ana, CA 92705 | |||
| Website | nkgenbiotech.com | |||
| Country | United States | |||
| Year Founded | 2017 | |||
| Profitability | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -97.34% | |||
| Return on Equity | -- | |||
| Income Statement | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -30.11M | |||
| EBIT (TTM) | -31.30M | |||
| Net Income (TTM) | -48.48M | |||
| Net Income Avl. to Common (TTM) | -48.48M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 119.89% | |||
| EPS Diluted (TTM) | -2.31 | |||
| EPS Diluted Growth (Q YOY) | 106.16% | |||
| Balance Sheet | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 8.00K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 911.00K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -47.05M | |||
| Current Ratio (Q) | 0.025 | |||
| Book Value Per Share (Q) | -$1.32 | |||
| Total Assets (Q) | 15.00M | |||
| Total Current Liabilities (Q) | 37.12M | |||
| Total Debt (Q) | 30.74M | |||
| Total Liabilities (Q) | 62.05M | |||
| Total Common Equity (Q) | -47.05M | |||
| Cash Flow | NKGN - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -15.00K | |||
| Cash from Financing (TTM) | 12.08M | |||
| Net Change in Cash (TTM) | -8.80M | |||
| Levered Free Cash Flow (TTM) | -31.33M | |||
| Cash from Operations (TTM) | -20.87M | |||
